Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Phase 3 failure

- PMLiVE

Takeda UK & Ireland appoints market access director

Peter Wheatley Price brings experience from GSK, Janssen and Boehringer Ingelheim

- PMLiVE

Takeda agrees $5.2bn deal to buy Ariad

Acquires cancer firm in the first big pharma M&A deal of 2017

- PMLiVE

Valeant’s proposed sale of Salix to Takeda ‘in jeopardy’

Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands

dengue fever mosquito

Takeda plans German plant to support dengue vaccine roll-out

Will invest more than €100m in the Singen manufacturing facility

- PMLiVE

Takeda gets EU green light for oral myeloma drug

Ninlaro first oral proteasome inhibitor to be registered in Europe

- PMLiVE

Takeda and Marvel launch IBD superhero squad

The comic book initiative aims to raise awareness of the gastrointestinal disease

Bristol Myers Squibb logo

BMS wins early UK access for Opdivo in Hodgkin’s lymphoma

Cancer treatment approved by the MHRA for use before EU licence in place

- PMLiVE

Takeda launches drug discovery biotech

Hopes Bridge Medicines will streamline the development process

Takeda appoints UK & Ireland digital lead

Marc Weeks takes up the newly-established role

Deal Watch September 2016

Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up

- PMLiVE

Biologics set to revolutionise the gastrointestinal market

Patent expirations and new approvals will see it grow to $48.4bn by 2020

- PMLiVE

Alnylam pulls lead drug revusiran after deaths in phase III trial

US biotech has yet to determine the cause of the amyloidosis and cardiomyopathy study fatalities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links